Example of Molecular Cancer Research format
Recent searches

Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format Example of Molecular Cancer Research format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access ISSN: 15417786 e-ISSN: 15573125

Molecular Cancer Research — Template for authors

Categories Rank Trend in last 3 yrs
Oncology #50 of 340 down down by 9 ranks
Molecular Biology #69 of 382 down down by 4 ranks
Cancer Research #49 of 207 down down by 11 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 695 Published Papers | 6048 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 20/07/2020
Insights & related journals
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Journal Performance & Insights

  • Impact Factor
  • CiteRatio
  • SJR
  • SNIP

Impact factor determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

4.63

3% from 2018

Impact factor for Molecular Cancer Research from 2016 - 2019
Year Value
2019 4.63
2018 4.484
2017 4.597
2016 4.974
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 3% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

CiteRatio is a measure of average citations received per peer-reviewed paper published in the journal.

8.7

23% from 2019

CiteRatio for Molecular Cancer Research from 2016 - 2020
Year Value
2020 8.7
2019 7.1
2018 7.9
2017 8.7
2016 8.9
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 23% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR) measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

2.273

5% from 2019

SJR for Molecular Cancer Research from 2016 - 2020
Year Value
2020 2.273
2019 2.389
2018 2.381
2017 2.428
2016 2.496
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 5% in last years.
  • This journal’s SJR is in the top 10 percentile category.

Source Normalized Impact per Paper (SNIP) measures actual citations received relative to citations expected for the journal's category.

1.157

6% from 2019

SNIP for Molecular Cancer Research from 2016 - 2020
Year Value
2020 1.157
2019 1.094
2018 1.111
2017 1.108
2016 1.132
graph view Graph view
table view Table view

insights Insights

  • SNIP of this journal has increased by 6% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Related Journals

open access Open Access ISSN: 15537390 e-ISSN: 15537404
recommended Recommended

PLOS

CiteRatio: 9.0 | SJR: 3.587 | SNIP: 1.457
open access Open Access ISSN: 8876924 e-ISSN: 14765551
recommended Recommended

Nature

CiteRatio: 16.0 | SJR: 4.539 | SNIP: 2.28
open access Open Access ISSN: 85472 e-ISSN: 15387445
recommended Recommended

American Association for Cancer Research

CiteRatio: 15.8 | SJR: 4.103 | SNIP: 1.983
open access Open Access ISSN: 10780432 e-ISSN: 15573265
recommended Recommended

American Association for Cancer Research

CiteRatio: 18.2 | SJR: 5.427 | SNIP: 2.243
Molecular Cancer Research

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

American Association for Cancer Research

Molecular Cancer Research

Molecular Cancer Research publishes original, novel, and well-designed studies on the molecular and cellular aspects of cancer biology. Papers should represent significant new information gathered from basic research that has implications for cancer therapeutics in one of the ...... Read More

Oncology

Molecular Biology

Cancer Research

Medicine

i
Last updated on
20 Jul 2020
i
ISSN
1541-7786
i
Impact Factor
High - 1.213
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
Vancouver
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder GE, Tinkham M, Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent con-version. Phys Rev B. 1982;25(7):4515–4532. Available from: 10.1103/PhysRevB.25.4515.

Top papers written in this journal

open accessOpen access Journal Article
Reduced accumulation of specific microRNAs in colorectal neoplasia.

Abstract:

Short non-coding RNAs are known to regulate cellular processes including development, heterochromatin formation, and genomic stability in eukaryotes. Given the impact of these processes on cellular identity, a study was undertaken to investigate possible changes in microRNA (miRNA) levels during tumorigenesis. A total of 28 d... Short non-coding RNAs are known to regulate cellular processes including development, heterochromatin formation, and genomic stability in eukaryotes. Given the impact of these processes on cellular identity, a study was undertaken to investigate possible changes in microRNA (miRNA) levels during tumorigenesis. A total of 28 different miRNA sequences was identified in a colonic adenocarcinoma and normal mucosa, including 3 novel sequences and a further 7 that had previously been cloned only from mice. Human homologues of murine miRNA sequences, miR-143 and miR-145, consistently display reduced steady-state levels of the mature miRNA at the adenomatous and cancer stages of colorectal neoplasia. read more read less

Topics:

microRNA (52%)52% related to the paper, Intestinal mucosa (51%)51% related to the paper
View PDF
1,657 Citations
open accessOpen access Journal Article DOI: 10.1158/1541-7786.MCR-07-0324
Histone Deacetylase Inhibitors: Overview and Perspectives
Milos Dokmanovic1, Cathy Clarke, Paul A. Marks

Abstract:

Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses... Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death. read more read less

Topics:

Vorinostat (68%)68% related to the paper, Histone deacetylase 2 (64%)64% related to the paper, Histone deacetylase 5 (63%)63% related to the paper, HDAC11 (63%)63% related to the paper, HDAC10 (61%)61% related to the paper
View PDF
1,058 Citations
open accessOpen access Journal Article DOI: 10.1158/1541-7786.MCR-05-0261
Inflammation, a key event in cancer development.
Haitian Lu1, Weiming Ouyang, Chuanshu Huang

Abstract:

Several recent studies have identified nuclear factor-κB as a key modulator in driving inflammation to cancers. Besides this transcription factor, essential in regulating inflammation and cancer development, an inflammatory microenvironment inhabiting various inflammatory cells and a network of signaling molecules are also in... Several recent studies have identified nuclear factor-κB as a key modulator in driving inflammation to cancers. Besides this transcription factor, essential in regulating inflammation and cancer development, an inflammatory microenvironment inhabiting various inflammatory cells and a network of signaling molecules are also indispensable for the malignant progression of transformed cells, which is attributed to the mutagenic predisposition of persistent infection-fighting agents at sites of chronic inflammation. As a subverted host response to inflammation-induced tumors, the inflammatory cells and regulators may facilitate angiogenesis and promote the growth, invasion, and metastasis of tumor cells. Thus far, research regarding inflammation-associated cancer development has focused on cytokines and chemokines as well as their downstream targets in linking inflammation and cancer. Moreover, other proteins with extensive roles in inflammation and cancer, such as signal transducers and activators of transcription, Nrf2, and nuclear factor of activated T cells, are also proposed to be promising targets for future studies. The elucidation of their specific effects and interactions will accelerate the development of novel therapeutic interventions against cancer development triggered by inflammation. (Mol Cancer Res 2006;4(4):221–33) read more read less

Topics:

Inflammation (54%)54% related to the paper, Metastasis (54%)54% related to the paper, Angiogenesis (51%)51% related to the paper
View PDF
923 Citations
open accessOpen access Journal Article
The MDM2-p53 Interaction
Ute M. Moll1, Oleksi Petrenko

Abstract:

Activation of the p53 protein protects the organism against the propagation of cells that carry damaged DNA with potentially oncogenic mutations. MDM2, a p53-specific E3 ubiquitin ligase, is the principal cellular antagonist of p53, acting to limit the p53 growth-suppressive function in unstressed cells. In unstressed cells, ... Activation of the p53 protein protects the organism against the propagation of cells that carry damaged DNA with potentially oncogenic mutations. MDM2, a p53-specific E3 ubiquitin ligase, is the principal cellular antagonist of p53, acting to limit the p53 growth-suppressive function in unstressed cells. In unstressed cells, MDM2 constantly monoubiquitinates p53 and thus is the critical step in mediating its degradation by nuclear and cytoplasmic proteasomes. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Disruption of the p53-MDM2 complex by multiple routes is the pivotal event for p53 activation, leading to p53 induction and its biological response. Because the p53-MDM2 interaction is structurally and biologically well understood, the design of small lipophilic molecules that disrupt or prevent it has become an important target for cancer therapy. read more read less

Topics:

Ubiquitin ligase (55%)55% related to the paper, Mdm2 (53%)53% related to the paper, Proto-Oncogene Proteins c-mdm2 (52%)52% related to the paper, Proteasome (51%)51% related to the paper
View PDF
755 Citations
open accessOpen access Journal Article DOI: 10.1158/1541-7786.MCR-08-0393
Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Abstract:

Tumor contains small population of cancer stem cells (CSC) that are responsible for its maintenance and relapse. Analysis of these CSCs may lead to effective prognostic and therapeutic strategies for the treatment of cancer patients. We report here the identification of CSCs from human lung cancer cells using Aldefluor assay ... Tumor contains small population of cancer stem cells (CSC) that are responsible for its maintenance and relapse. Analysis of these CSCs may lead to effective prognostic and therapeutic strategies for the treatment of cancer patients. We report here the identification of CSCs from human lung cancer cells using Aldefluor assay followed by fluorescence-activated cell sorting analysis. Isolated cancer cells with relatively high aldehyde dehydrogenase 1 (ALDH1) activity display in vitro features of CSCs, including capacities for proliferation, self-renewal, and differentiation, resistance to chemotherapy, and expressing CSC surface marker CD133. In vivo experiments show that the ALDH1-positive cells could generate tumors that recapitulate the heterogeneity of the parental cancer cells. Immunohistochemical analysis of 303 clinical specimens from three independent cohorts of lung cancer patients and controls show that expression of ALDH1 is positively correlated with the stage and grade of lung tumors and related to a poor prognosis for the patients with early-stage lung cancer. ALDH1 is therefore a lung tumor stem cell-associated marker. These findings offer an important new tool for the study of lung CSCs and provide a potential prognostic factor and therapeutic target for treatment of the patients with lung cancer. (Mol Cancer Res 2009;7(3):330–8) read more read less

Topics:

Cancer stem cell (71%)71% related to the paper, Cancer (66%)66% related to the paper, Lung cancer (62%)62% related to the paper, CA15-3 (61%)61% related to the paper, Cancer cell (58%)58% related to the paper
View PDF
693 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Molecular Cancer Research.

It automatically formats your research paper to American Association for Cancer Research formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Molecular Cancer Research format uses Vancouver citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

Absolutely not! With our tool, you can freely write without having to focus on LaTeX. You can write your entire paper as per the Molecular Cancer Research guidelines and autoformat it.

Yes. The template is fully compliant as per the guidelines of this journal. Our experts at SciSpace ensure that. Also, if there's any update in the journal format guidelines, we take care of it and include that in our algorithm.

Sure. We support all the top citation styles like APA style, MLA style, Vancouver style, Harvard style, Chicago style, etc. For example, in case of this journal, when you write your paper and hit autoformat, it will automatically update your article as per the Molecular Cancer Research citation style.

You can avail our Free Trial for 7 days. I'm sure you'll find our features very helpful. Plus, it's quite inexpensive.

Yup. You can choose the right template, copy-paste the contents from the word doc and click on auto-format. You'll have a publish-ready paper that you can download at the end.

A matter of seconds. Besides that, our intuitive editor saves a load of your time in writing and formating your manuscript.

One little Google search can get you the Word template for any journal. However, why do you need a Word template when you can write your entire manuscript on SciSpace, autoformat it as per Molecular Cancer Research's guidelines and download the same in Word, PDF and LaTeX formats? Try us out!.

Absolutely! You can do it using our intuitive editor. It's very easy. If you need help, you can always contact our support team.

SciSpace is an online tool for now. We'll soon release a desktop version. You can also request (or upvote) any feature that you think might be helpful for you and the research community in the feature request section once you sign-up with us.

Sure. You can request any template and we'll have it up and running within a matter of 3 working days. You can find the request box in the Journal Gallery on the right sidebar under the heading, "Couldn't find the format you were looking for?".

After you have written and autoformatted your paper, you can download it in multiple formats, viz., PDF, Docx and LaTeX.

To be honest, the answer is NO. The impact factor is one of the many elements that determine the quality of a journal. Few of those factors the review board, rejection rates, frequency of inclusion in indexes, Eigenfactor, etc. You must assess all the factors and then take the final call.

SHERPA/RoMEO Database

We have extracted this data from Sherpa Romeo to help our researchers understand the access level of this journal. The following table indicates the level of access a journal has as per Sherpa Romeo Archiving Policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

The 5 most common citation types in order of usage are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

Our journal submission experts are skilled in submitting papers to various international journals.

After uploading your paper on SciSpace, you would see a button to request a journal submission service for Molecular Cancer Research.

Each submission service is completed within 4 - 5 working days.

Yes. SciSpace provides this functionality.

After signing up, you would need to import your existing references from Word or .bib file.

SciSpace would allow download of your references in Molecular Cancer Research Endnote style, according to american-association-for-cancer-research guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Molecular Cancer Research formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template